RxDoctor Payments DataLook up a doctor →

Adekunle Adekola, MD

Critical Care Medicine · Lewisville, TXNPI 1588685770

Payments from drug & device makers

$31,347in general payments, 2019–2025

Across 486 payments — averaging $64.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$24K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Mylan Specialty L.p.$664
  • Insmed, Inc.$302
  • Sunovion Pharmaceuticals Inc.$274
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,80399%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,347 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$168,450
Medicare patients
485
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter287$213,793
Breztri AerosphereBudesonide/Glycopyr/Formoterol144$106,363
Spiriva RespimatTiotropium Bromide37$32,395
SymbicortBudesonide/Formoterol Fumarate78$24,953
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$24,608
Breo ElliptaFluticasone/Vilanterol49$24,341
Combivent RespimatIpratropium/Albuterol Sulfate15$8,953
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,738
Advair HfaFluticasone Propion/Salmeterol23$7,041
Albuterol Sulfate HfaAlbuterol Sulfate208$6,544
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$6,020
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$5,164
BreynaBudesonide/Formoterol Fumarate14$3,830
Montelukast Sodium207$1,700
Ventolin HfaAlbuterol Sulfate25$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,168$262,742363 claims
AstraZenecaBreztri Aerosphere, Symbicort$23,746$131,317222 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$1,577$50,08670 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →